بيتا
رادار التجارب AI
حالة التجربة السريرية NCT06018194 لـ مرض الشريان التاجي هي قيد التجنيد. اطلعوا على جميع التفاصيل في عرض البطاقة الخاص برادار التجارب السريرية وأدوات اكتشاف الذكاء الاصطناعي. أو يمكنكم طرح أي سؤال هنا.
تجربة واحدة تطابق معايير الفلتر
عرض البطاقة

ELUCIDATE FFRct Study

قيد التجنيد
تفاصيل التجربة السريرية متاحة بشكل أساسي باللغة الإنجليزية. ومع ذلك، يمكن لـ 'رادار التجارب AI' أن يساعدك؛ ما عليك سوى النقر على 'وصف الدراسة' لعرض ومناقشة معلومات التجربة باللغة التي اخترتها.
التجربة السريرية NCT06018194 هي دراسة رصدية لـمرض الشريان التاجي وهي قيد التجنيد. بدأت في ١٦ صفر ١٤٤٥ هـ مع خطة لتجنيد ٣٥٠ مشاركًا. يقودها Elucid Bioimaging Inc.، ومن المتوقع اكتمالها بحلول ٢٥ محرم ١٤٤٦ هـ. تم تحديث البيانات الأخيرة من ClinicalTrials.gov في ١٠ شعبان ١٤٤٥ هـ.
الملخص
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR).

Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.

وصف مفصل
Invasive fractional flow reserve is a clinically validated measure of lesion-specific ischemia and is preferred over visual estimation of diameter stenosis for clinical decision-making regarding coronary revascularization in patients with stable clinical presentations. Fractional flow reserve derived from coronary computed tomography angiography (FFRct) using computational fluid dynamic (CFD)-based software has been shown to be a reasonably accurate estimate of invasive FFR and is included in contemporary guidelines as a decision-tool for management of patients with intermediate stenosis on CCTA. However, CFD-based FFRct is calculated based predominately on detailed coronary lumen geometry. It is understood that the burden and type of coronary atherosclerosis, in addition to lumen geometry, significantly impacts the vasodilatory capacity of the coronary endothelium.

Preliminary studies suggest that invasive FFR can be accurately estimated based on the quantification of coronary plaque burden and the assessment of plaque composition. Previously, the investigators have demonstrated that a novel plaque-based FFRct approach, using a histologically validated software (ElucidVivoTM) for the measurement of plaque morphology (volume, plaque risk characteristics, and stenosis) to train a deep-learning model, was shown to be accurate and superior to lumen stenosis for predicting invasive FFR in a single-site feasibility study.

In this study, the investigators seek to assess the diagnostic accuracy of the Elucid plaque-based FFRct software to estimate invasive FFR in patients at multiple centers.

العنوان الرسمي

The ELUCIDATE FFRct Study

الحالات الطبية
مرض الشريان التاجي
المنشورات
مقالات علمية وأوراق بحثية منشورة حول هذه التجربة السريرية:
معرّفات دراسة أخرى
  • 3-ST-03-03
NCT معرّف
تاريخ البدء (فعلي)
2023-09-01
آخر تحديث مُنشور
2024-02-20
تاريخ الاكتمال (المقدر)
2024-07-31
عدد المشاركين المخطط لهم
٣٥٠
نوع الدراسة
رصدية
الحالة
قيد التجنيد
الكلمات الرئيسية
coronary computed tomographic angiography
coronary CTA
cardiac CT
fractional flow reserve
plaque
مجموعات/التدخلات
مجموعة المشاركين/مجموعةتَدَخُّل/علاج
Low FFR
Invasive FFR \<= 0.80
Elucidvivo
Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
High FFR
Invasive FFR \> 0.80
Elucidvivo
Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
النتيجة الرئيسية
مقياس النتيجةوصف القياسالإطار الزمني
Sensitivity of FFRct versus invasive FFR for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Specificity of FFRct versus invasive FFR for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
النتيجة الثانوية
مقياس النتيجةوصف القياسالإطار الزمني
Sensitivity of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Specificity of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Area under the receiver-operating characteristic curve (AUC) of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Area under the receiver-operating characteristic curve (AUC) of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Accuracy of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Accuracy of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Negative predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Negative predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Positive predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Positive predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
معايير الأهلية

الأعمار المؤهلة للدراسة
بالغ, كبار السن
العمر الأدنى للدراسة
18 Years
الجنس المؤهل
الكل

- Adults >=18 years with at least one 30-90% stenosis on CCTA (>64- detector row) performed within 60 days of undergoing invasive FFR.

  • History of coronary revascularization with coronary artery bypass graft (CABG) surgery and/or percutaneous coronary intervention (PCI) (stent or balloon angioplasty) prior to CCTA and invasive FFR.
  • History of myocardial infarction prior to CCTA and invasive FFR.
  • Known complex congenital heart disease.
  • Existing pacemaker or internal defibrillator lead implantation(s).
  • Existing prosthetic heart valve.
  • Absence of CCTA Digital Imaging and Communications in Medicine (DICOM) data for analysis.
  • Absence of invasive coronary angiography imaging or adequate description defining the position of the invasive FFR wire location.
  • Poor CCTA image quality that does not meet Elucid image processing requirements for plaque and FFRct.
  • Absence of study date for CCTA or invasive FFR.
  • Interval clinical myocardial infarction, diagnosis of decompensated heart failure, stroke, or coronary revascularization procedure between CCTA and invasive FFR.
  • Non-diagnostic CCTA or invasive FFR. Studies where the results of the study were deemed non-diagnostic for clinical decision-making will be excluded.
  • CCTA or invasive FFR studies performed prior to 1 January 2016.
Elucid Bioimaging Inc. logoElucid Bioimaging Inc.
Lundquist Institute at Harbor-UCLA Medical Center logoLundquist Institute at Harbor-UCLA Medical Center
جهة اتصال مركزية للدراسة
جهة اتصال: Todd C Villines, MD, 978-468-0508, [email protected]
جهة اتصال: John Aluru, MBBS, 978-468-0508, [email protected]
9 مواقع الدراسة في 1 بلدان

California

Cardiovascular Medical Group of Southern California, Beverly Hills, California, 90210, United States
Ronald P Karlsberg, MD, جهة اتصال
لم يبدأ التجنيد بعد

Georgia

Piedmont Healthcare, Atlanta, Georgia, 30309, United States
Venkateshwar Polsani, MD, جهة اتصال
لم يبدأ التجنيد بعد

Indiana

Parkview Health, Fort Wayne, Indiana, 46845, United States
Dustin Thomas, MD, جهة اتصال
لم يبدأ التجنيد بعد

Kansas

Midwest Heart and Vascular Specialists, Overland Park, Kansas, 66211, United States
Stephen A Bloom, MD, جهة اتصال
قيد التجنيد

New Jersey

Valley Health System, Ridgewood, New Jersey, 07450, United States
Himanshu Gupta, MD, جهة اتصال
لم يبدأ التجنيد بعد

Ohio

Cleveland Clinic, Cleveland, Ohio, 44195, United States
Milind Desai, MD, MBA, جهة اتصال
لم يبدأ التجنيد بعد

Tennessee

Centennial Heart, Nashville, Tennessee, 37203, United States
David Huneycutt, MD, جهة اتصال
لم يبدأ التجنيد بعد
Ascension Medical Group, Nashville, Tennessee, 37205, United States
Andrew O Zurich, MD, جهة اتصال
لم يبدأ التجنيد بعد

Virginia

University of Virginia, Charlottesville, Virginia, 22908, United States
Patricia Rodriguez-Lozano, MD, جهة اتصال
قيد التجنيد